181 related articles for article (PubMed ID: 35402282)
21. Pathogenic germline variants in patients with breast cancer: conversations across generations, practices and patients' attitude.
Abdel-Razeq H; Mustafa R; Abdel-Razeq S; Abu-Fares H; Al Masri S; Damsees R; El-Atrash M; Elemian S; Alkyam M; Ammar K; Bater R; Kderat M; Alhajahjeh A
Front Genet; 2023; 14():1194075. PubMed ID: 37920853
[No Abstract] [Full Text] [Related]
22. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling.
Richter S; Haroun I; Graham TC; Eisen A; Kiss A; Warner E
Ann Oncol; 2013 Nov; 24 Suppl 8():viii69-viii74. PubMed ID: 24131974
[TBL] [Abstract][Full Text] [Related]
23.
Huszno J; Pigłowski W; Mazur M; Pamuła-Piłat J; Zajkowicz A; Kierzkowska AF; Wojciechowska MO
Mol Clin Oncol; 2021 Nov; 15(5):222. PubMed ID: 34548921
[TBL] [Abstract][Full Text] [Related]
24. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
25. Reclassification of
Ha HI; Ryu JS; Shim H; Kong SY; Lim MC
J Gynecol Oncol; 2020 Nov; 31(6):e83. PubMed ID: 33078592
[TBL] [Abstract][Full Text] [Related]
26. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Spearman AD; Sweet K; Zhou XP; McLennan J; Couch FJ; Toland AE
J Clin Oncol; 2008 Nov; 26(33):5393-400. PubMed ID: 18824701
[TBL] [Abstract][Full Text] [Related]
27. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
Eccles DM; Mitchell G; Monteiro AN; Schmutzler R; Couch FJ; Spurdle AB; Gómez-García EB;
Ann Oncol; 2015 Oct; 26(10):2057-65. PubMed ID: 26153499
[TBL] [Abstract][Full Text] [Related]
28. Germline
Mehta A; Vasudevan S; Sharma SK; Kumar D; Panigrahi M; Suryavanshi M; Gupta G
Cancer Manag Res; 2018; 10():6505-6516. PubMed ID: 30555256
[TBL] [Abstract][Full Text] [Related]
29. Reclassification of
Lee JS; Oh S; Park SK; Lee MH; Lee JW; Kim SW; Son BH; Noh DY; Lee JE; Park HL; Kim MJ; Cho SI; Lee YK; Park SS; Seong MW
J Med Genet; 2018 Dec; 55(12):794-802. PubMed ID: 30415210
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and oncologic outcomes of
Seo JH; Jeong SY; Kim MS; Kang JH; Paik ES; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
Obstet Gynecol Sci; 2019 Nov; 62(6):411-419. PubMed ID: 31777737
[TBL] [Abstract][Full Text] [Related]
31. A Population-Based Analysis of
Park KS; Lee W; Seong MW; Kong SY; Lee KA; Ha JS; Cho EH; Han SH; Park I; Kim JW
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34063308
[TBL] [Abstract][Full Text] [Related]
32. Functional Characterization of
Boonen RACM; Vreeswijk MPG; van Attikum H
Front Mol Biosci; 2020; 7():169. PubMed ID: 33195396
[TBL] [Abstract][Full Text] [Related]
33. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
34. Genetic Variation and the Role of Multigene Panel Testing for Hereditary Breast Cancer: A Single-Institution Experience.
Lu K; Smith M; Kanderi T; Verbiar J; Laspe J; Bair L; Torp L
Cureus; 2021 Apr; 13(4):e14637. PubMed ID: 34046273
[TBL] [Abstract][Full Text] [Related]
35. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions.
Murray ML; Cerrato F; Bennett RL; Jarvik GP
Genet Med; 2011 Dec; 13(12):998-1005. PubMed ID: 21811163
[TBL] [Abstract][Full Text] [Related]
36. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Tram E; Savas S; Ozcelik H
PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
[TBL] [Abstract][Full Text] [Related]
38. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice.
Petrucelli N; Lazebnik N; Huelsman KM; Lazebnik RS
Genet Test; 2002; 6(2):107-13. PubMed ID: 12215249
[TBL] [Abstract][Full Text] [Related]
39. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Lindor NM; Guidugli L; Wang X; Vallée MP; Monteiro AN; Tavtigian S; Goldgar DE; Couch FJ
Hum Mutat; 2012 Jan; 33(1):8-21. PubMed ID: 21990134
[TBL] [Abstract][Full Text] [Related]
40. GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes.
Caleca L; Colombo M; van Overeem Hansen T; Lázaro C; Manoukian S; Parsons MT; Spurdle AB; Radice P
Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30696104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
